Lipotoxicity
cardiomyopathy is the result of excessive accumulation and oxidation of toxic
lipids in the heart. It is a major threat to patients with diabetes.
Glucagon-like peptide-1 (GLP-1) has aroused considerable interest as a novel therapeutic target for
diabetes mellitus because it stimulates insulin secretion. Here, we investigated the effects and mechanisms of the
GLP-1 analog
exendin-4 and the dipeptidyl peptidase-4 inhibitor
saxagliptin on cardiac lipid metabolism in diabetic mice (DM). The increased myocardial
lipid accumulation, oxidative stress, apoptosis, and cardiac remodeling and dysfunction induced in DM by low
streptozotocin doses and high-fat diets were significantly reversed by
exendin-4 and
saxagliptin treatments for 8 weeks. We found that
exendin-4 inhibited abnormal activation of the (PPARα)-CD36 pathway by stimulating
protein kinase A (PKA) but suppressing the Rho-associated
protein kinase (ROCK) pathway in DM hearts,
palmitic acid (PA)-treated rat h9c2 cardiomyocytes (CMs), and isolated adult mouse CMs. Cardioprotection in DM mediated by
exendin-4 was abolished by combination
therapy with the PPARα agonist
wy-14643 but mimicked by PPARα gene deficiency. Therefore, the PPARα pathway accounted for the effects of
exendin-4. This conclusion was confirmed in cardiac-restricted overexpression of PPARα mediated by adeno-associated virus serotype-9 containing a cardiac
troponin T promoter. Our results provide the first direct evidence that
GLP-1 protects cardiac function by inhibiting the ROCK/PPARα pathway, thereby ameliorating lipotoxicity in
diabetic cardiomyopathy.